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Fluorescence anisotropyThree synthetic peptide sequences of 18 amino acid each, corresponding to different fragments of the E2 capsid
protein of GB virus C (GBV-C): SDRDTVVELSEWGVPCAT (P45), GSVRFPFHRCGAGPKLTK (P58) and
RFPFHRCGAGPKLTKDLE (P59) have been characterized in order to ﬁnd a relationship between their physico-
chemical properties and the results obtained in cellular models. Experiments were performed in presence and
absence of the HIV fusion peptide (FP-HIV) due to the evidences that GBV-C inhibits AIDS progression. P45 pep-
tide showed lower surface activity and less extent of penetration into 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC) and 1,2-dimyristoyl-sn-glycero-3-phospho-L-serine (DMPS) (3:2, mol/mol) lipid
monolayers than P58 and P59. However, P45 peptide presented higher capacity to inhibit FP-HIV induced cell–
cell fusion than the other two sequences. These results were supported by ﬂuorescence anisotropy measure-
ments which indicated that P45 had a signiﬁcant effect on the inhibition of FP-HIV perturbation of liposomes
of the same lipid composition. Finally, atomic force microscopy (AFM) studies have evidenced the modiﬁcation
of the changes induced by the FP-HIV in the morphology of lipid bilayers when P45 was present in the medium.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
There are uncountable studies in the literature dealing with the use
of synthetic peptides as simple tools for unraveling the properties of
proteins involved in a great variety of processes or even substituting
the whole protein for a speciﬁc function [1]. Peptides have been de-
signed and synthesized for therapeutic applications. For instance as a
treatment for autoimmune and rheumatic diseases [2,3], several
modes of cancer [4–7] or as inhibitors of HIV-1 reverse transcriptase
and integrase [8]. Due to the advantageous properties of synthetic pep-
tides compared to biological molecules there is an increasing interest in
replacing biological antigens by synthetic peptides as well as the use of
site-speciﬁc antibodies induced with synthetic peptides in vaccine de-
sign [9–12]. Diagnosis has been another extensive application of syn-
thetic peptides with successful results in autoimmune [13], HIV [14]
and several forms of hepatitis infections [15,16], amyloid related dis-
eases [17] or rheumatoid arthritis [3,18]. The interest of the synthetic
peptides is supported by the increasing number of patents published.
Frommore than two decades, our grouphas beenworkingwith pep-
tide sequences corresponding to fragments of structural and non-
structural capsid proteins of hepatitis variants [15,18,19].More recently,34 934 035 987.the evidence that the coexistence of GB virus C (GBV-C) andHIV is relat-
ed to a decrease in AIDS progression has focused our efforts in the selec-
tion, synthesis and physicochemical characterization of GBV-C
sequences and the analysis of their interaction with the HIV fusion pep-
tide (FP-HIV). The studies were mainly based on the analysis of GBV-C
peptides, FP-HIV, and their combination at different molar ratios in so-
lution aswell as their behavior in presence of lipidmonolayers and lipo-
somes as model membranes [20,21].
Despite the data obtained up to now studying the interaction of pep-
tide sequenceswithmono and bilayers ourmain concern is toﬁnd a good
correlation between the results obtained in vitrowith those in vivo. In ad-
dition, we would like to ﬁgure out what is the role of GBV-C peptides in
the decrease of HIV infectivity. To get insight into this aspect, we have
chosen three peptide sequences SDRDTVVELSEWGVPCAT (P45),
GSVRFPFHRCGAGPKLTK (P58) and RFPFHRCGAGPKLTKDLE (P59) corre-
sponding to the E2 capsid protein of GBV-C that have shown different ac-
tivity in several experiments. Thus, P45 and P59 showed inhibitory effect
on the FP-HIV induced leakage assay but only P45 was capable to inhibit
FP-HIV induce cell-cell fusion [22]. In the present paper, we compare
the surface properties of these peptides alone or in presence of FP-HIV
with the Langmuir technique [23] by analyzing both the ability of the
peptides to change the surface activity of a buffered saline solution
and, their incorporation into lipid monolayers of 1,2-dimyristoyl-sn-
glycero-3-phosphocholine (DMPC) and 1,2-dimyristoyl-sn-glycero-3-
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chosen for being a good model that mimics the lipid composition of
the membranes infected by HIV [24,25]. Fluorescence anisotropy mea-
surements with large unilamellar liposomes (LUVs) of the same lipid
composition were used to measure the penetration depth of the pep-
tides into the bilayer. Finally, atomic force microscopy (AFM) [26] was
chosen to determine the morphological changes in the surface of
DMPC/DMPS (3:2, mol/mol) supported lipid bilayers (SLB) driven by
P45 in presence and absence of FP-HIV. Results conclude that P45 is likely
the best candidate to inhibit FP-HIV.
2. Materials and methods
The phospholipids used in this study were 1,2-dimyristoyl-sn-
glycero-3-phosphocholine (DMPC) and 1,2-dimyristoyl-sn-glycero-3-
phospho-L-serine (sodium salt) (DMPS) from Avanti Polar Lipids
(Alabaster, Al.). The lipids were pure as determined by thin layer chro-
matography and used as received. A mixture of chloroform andmetha-
nol (2:1, v/v) (HPLC gradeMerck, Germany)was used to dissolve and as
spreading solvent for all lipids. Water used was doubly distilled and de-
ionized (Milli-Q system, Millipore Corp. 18.3 MΩ cm, resistivity).
Peptides in the amidated formwere obtained by solid-phase peptide
synthesis as previously described [22]. Stock peptide solutions of 1 mM
were prepared in 20% acetonitrile (HPLC grade, Merck) in water.
The ﬂuorescent probes 1-(4-trimethylammoniumphenyl)-6-phenyl-
1,3,5-hexatriene p-toluenesulfonate (TMA-DPH) and 1,6-diphenyl-
1,3,5-hexatriene (DPH) were purchased from Molecular Probes, Inc.
(Invitrogen, Cralsbad, CA).
2.1. Surface activity measurements
The surface properties of the peptides were analyzed as described
elsewhere [19] in a NIMA (Conventry, UK) ﬁlm balance equipped
with a Wilhelmy platinum plate and a round Teﬂon® dish (surface
area 19.6 cm2, 27.2 cm3 of capacity) with Tris 10 mM, pH 7.4 as the
subphase. The Teﬂon® trough and the plate were thoroughly cleaned
before each run with chloroform and boiling water to avoid carry-
over of lipid. Increasing volumes of a concentrated solution of the
peptide were injected beneath the surface through a lateral whole. Dur-
ing the experiments, the subphasewas continuously stirred. Surface pres-
sure (π) with time was recorded until a steady-state value was obtained.
2.2. Peptide insertion into lipid monolayers
The kinetics of peptide binding to the lipid monolayers were moni-
tored with the same Teﬂon® trough described above. Lipid monolayers
at the required initial surface pressure, πo, (5, 10, 20 or 32 mN m−1)
were formed by spreading the lipid from chloroform/methanol
(2:1, v/v) solutions onto Tris 10 mM, pH 7.4 subphases. After 20 min
for solvent evaporation and to assure monolayer stability, the peptide
was injected from a stock solution in H2O/ACN (1:1, v/v) beneath the
lipid monolayer. The subphase was stirred continuously to ensure a ho-
mogeneous distribution and a good interaction of the peptide with the
monolayer. Pressure increases (Δπ) with time were recorded until no
further changes occurred indicating that equilibrium was reached.
For each sample, the values of Δπ as a function of various πο values
were obtained. The plot of Δπ versus πο yields a straight line with nega-
tive slope which intersects the abscissa at a limiting surface pressure
that is deﬁned as the critical insertion pressure of the peptide for the
corresponding lipid monolayer [27].
2.3. Compression isotherms
The compression isothermswere performed on a Langmuir ﬁlm bal-
ance, NIMA equipped with a Wilhelmy platinum plate and a Teﬂon®
trough of 595 cm2 of surface area and a volume of 300 cm3. The outputof the pressure pickup was calibrated by recording the well-known iso-
therm of stearic acid that is characterized by a sharp phase transition at
25mNm−1 for a subphase of purewater at 20°C. Peptide solutionswere
prepared by solving the appropriate amount in chloroform.Monolayers
were formed by applying small drops of the spreading solutions on the
Tris subphase with a microsyringe (Hamilton Co., Reno, NV). After
20min for solvent evaporation, themonolayers of the desired composi-
tion were continuously compressed (symmetrical compression) with
an area reduction rate of 10 nm2 min−1 until the system had reached
its compression limit. The temperature of the subphase was 21 ±
0.5°C. All samples were run at least three times in the direction of in-
creasing pressure with freshly prepared ﬁlms. In addition and to assess
the stability of the monolayers, the ﬁlm was submitted to compression
and decompression cycles.
2.4. Liposome preparation
DMPC/DMPS (3:2, mol/mol) lipid vesicles were prepared as follows:
lipid mixture was dissolved in chloroform/methanol (2:1, v/v) and the
solution was dried by rotatory evaporation. The last traces of solvents
were removed by keeping the sample under vacuum for at least 24 h.
Tris buffer (10 mM, pH 7.4) was added to the lipids mixture to give a
ﬁnal concentration of 3.5 mM. Multilamellar vesicles (MLVs) were
then prepared by vortexing the lipids suspension during 10 min. Large
unilamellar vesicles (LUVs) were prepared by ten freeze–thaw cycles
ofMLVs followedby the extrusion of thepreparations ten times through
100 nm pore-size polycarbonate ﬁlters (Nucleopore, Pleasanton, CA,
USA) in a high pressure extruder (Lipex, Biomembranes, Vancouver,
Canada). All over the experiments, the temperature was 45°C, which
is above the transition temperature (Tm) of the lipid with higher Tm.
The size distribution of the vesicles was measured by dynamic
light scattering with a Zetasizer Nano instrument (Malvern, EU) at
25°C. The particle size distribution was designated by the polydis-
persity index, which ranged from 0.0 for an entirely monodisperse
sample, to 1.0 for a polydisperse sample. The z-average mean diam-
eter was ~120 nm and polydispersity around 0.15. The phospholipid
concentration of the preparations was determined by phosphorus
quantiﬁcation [28].
2.5. Fluorescence anisotropy of membrane lipids
Steady-state anisotropy measurements were carried with an Aminco
BowmanAB2 (Microbeam, SA) spectroﬂuorimeter using L-formatﬂuores-
cence polarizers. The dynamics of LUVs of DMPC/DMPS (3:2, mol/mol) in
presence of E2 peptides was determined by measuring the degree of de-
polarization of ﬂuorescence emitted from the probes DPH or TMA-DPH
[29].
The excitation and emission wavelength were 365 and 425 nm, re-
spectively for both probes (slit-widths: 4 nm). Labeled vesicles with
1% of the desired probe were mixed with the peptide in a 10 mM Tris
at pH 7.4, and anisotropywasmeasured automatically. For each sample,
two cycleswere done: a heating cycle from 15°C up to 40°C, followed by
a cooling cycle to the initial temperature, at 1°C intervals, allowing
5 min for thermal equilibration. All solutions were stirred continuously
during themeasurements. The temperaturewas controlledwith a peltier
system piloted by a computer program (Microbeam S.A., Barcelona,
Spain), and registered with a thermocouple inserted into the cuvette.
Fluorescence anisotropy I was calculated automatically by the software
provided with the instrument, according to Eq. (1):
r ¼ IVv−GIVh
IVv þ 2GIVh
ð1Þ
where IVv and IVh are ﬂuorescence intensities of the emitted polarized
light with the emission polarizer parallel or perpendicular, respectively,
Table 1
Peptide sequences and their physical chemistry properties. πsat: saturation pressure; K: concentration needed to reach half of themaximum pressure; Γ: surface excess concentration and
Area occupied per molecule.
Peptide Amino acid sequence Net charge pH 7.40 Isoelectric point πsat mNm−1 K nM Γ max mol m−2 Area nm2 molec−1
P 59 RFPFHRCGAGPKLTKDLE +3 10.58 13.8 166.9 1.29 × 10−6 1.29
P 58 GSVRFPFHRCGAGPKLTK +5 12.42 21.9 219.4 1.84 × 10−6 0.90
P 45 SDRDTVVELSEWGVPCAT −2 4.05 8.0 378.9 0.77 × 10−6 2.15
FP-HIV AVGIGALFLGFLGAAGSTMGAAS +1 14.0 79.5 521 4.75 × 10−6 0.35
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dencies in the detection system (G-factor correction: G = IHv/IHh).2.6. Atomic force microscopy
DMPC/DMPS (3:2, mol/mol) SLBs were prepared as described else-
where [30]. Brieﬂy, 50 μl of liposomes at 500 μM in 20 mM Tris,
150 mM NaCl, pH 7,40 and 10 mM CaCl2 were incubated onto freshly
cleaved mica at 50°C for 60 min. This method involved liposome
fusion which did not allow controlling the lipid asymmetry. Non-
adsorbed liposomes were eliminated by gently rinsing with the same
buffer without Ca2+. AFM intermittent contact mode images in
liquid were obtained using a Nanoscaope IV Multimode AFM (Bruker
AXS Corporation, Madison, WI) with MSNL silicon tips with a nominal
spring constant of 30 pN · nm−1. To minimize the applied force on
the sample set point was continuously adjusted during imaging. Images
were acquired at 0° scan angle at 1.5 Hz of scan rate. All images were
processed using the Bruker software.Table 2
Values of “lift-off” and extrapolated area or limiting indicate the area occupied by the
molecule in the monolayer.
Peptide Area lift-off (nm2 molec-1) Limiting Area (nm2 molec-1)
P 59 0.57 1.75
P 58 0.40 1.75
P 45 0.33 1.503. Results
3.1. Peptides characterization
The main objective of our study was focussed on the elucidation of
the physicochemical properties of three peptides corresponding to the
structural E2 capsid protein of GBV-C and their role in the inhibition of
the FP-HIV. The rationale for choosing these sequences were differences
found in previous experiments [22] that indicated the inhibitory activity
of P45 on FP-HIV (formerly named Gp-41)-mediated cell-cell fusion
assay in contrast to P58 and P59. First, we have compared their
amino acid sequence and charge at the physiological pH (buffered saline
solution, pH: 7.4) (Table 1). These sequenceswere selected froma series
of overlapping peptides with a length of 18 amino acids included in the
region 89–147 of the E2 capsid protein, [24]. Peptide neighbors differ
in three amino acids. Thus, P58 and P59 share the fragment
RFPFHRCGAGPKLTK and the three uncommon amino acids are DLE in
P58 and GSV in P59. While P59 is able to inhibit the leakage of contents
caused by FP-HIV in POPG liposomes, P58 doesn't. If we focus on the
charge of the peptides at the pH under study, it is +6 for P58 and +4
for P59 and this could be the responsible of the differences observed
in the test of inhibition of liposome leakage contents. On the other
hand, P45 has a completely different sequence without any fragment
in common having anionic character (−2). Charge is distributed along
the peptide chain in P58 and P59 but not so in P45 that is concentrated
in one side, conferring thus a hydrophobic character in the other side,
making the peptide more susceptible to interact with the FP-HIV pep-
tide that is positively charged. P45 shares with P59 its ability to inhibit
FP-HIV liposomes contents leakage but at different peptide/FP-HIV
molar ratio. In the case of P45/FP-HIV this ratio is 2:1 and for P59/FP-
HIV, 5:1. Solubility was similar for the three peptides that were solubi-
lized in acetonitrile/water (1:1, v/v) and therefore, differences in activ-
ity couldn't be attributed to hydrophobic/hydrophilic balance but to
amino acid distribution along the peptide chain. A data to be considered
is the ability to form hydrogen bonds with the medium that is around
33% for P58 and P59 and rises up to a 50% for P45.3.2. Peptides surface activity and interaction with lipid monolayers.
Peptides showed concentration dependency on its surface activity.
At low peptide concentrations the adsorption was gradual. The higher
the peptide concentration in the subphase, the faster the incorporation
process and the higher the surface pressure achieved. In all the cases,
the pressure reached a constant value after 60 minutes indicating the
equilibrium of the system. The shape of the surface activity curves ap-
proximates to a rectangular hyperbola and it was ﬁtted to Eq. (2):
π ¼ cπsat
K þ c ð2Þ
where c is the concentration, πsat is themaximum pressure reached and
K a constant that indicates the peptide concentration needed to reach
half πsat. A summary of the results is indicated in Table 1. Remarkably,
P58 had the highest πsat, almost three times higher than the measured
for P45.
By applying the Gibbs equation, the surface excess concentration (Γ)
of the peptides was calculated according to the equation:
Γ ¼ 1
RT
Δπ
Δ lnc
ð3Þ
beingR the gas constant, T the temperature (298 K),Δπ the surface pres-
sure increase achieved after 60 minutes, and c the concentration of
the peptide in the subphase. These results observed in Table 1, suggest
equilibrium between the molecules of the peptides in solution and
those at the air/water interface.
The surface excess concentration at saturation (Γmax) calculated
from the slope of the curve Δπ−Δ lnc can be found in Table 1. From
these values we calculated the surface molecular area (A) according to
the equation:
A ¼ 1
ΓmaxN
ð4Þ
where N is the Avogadro's constant.
Measurement of the surface activity of a molecule is a method
used to estimate themolecular surface area, which in the case of ﬂex-
ible molecules can provide information about its conformational be-
havior [31]. The molecular areas obtained (Table 1) indicate the
possibility of a α–helical conformation of the peptides with vertical
orientation at the air–water interface [32]. Therefore, these similari-
ties in molecular areas don't enable the discrimination of the pep-
tides activity in basis to conformational changes.
A further step in the differentiation of peptides behavior was fo-
cused on the study of their interaction with lipid monolayers by
Fig. 1. Fluorescence anisotropy studies of the three peptides in DMPC/DMPS (3:2,
mol/mol) LUVs labeled with the ﬂuorescent probe TMA-DPH. The peptide/lipid
molar ratio was 1:20 in buffered saline solution (Tris–HCl, pH: 7.4). Peptide and lipid
concentration into the cuvette were 5 μM and 75 μM, respectively. In the case of GBV-C/
FP-HIV, the peptide/peptide molar ratio was chosen according to the inhibition of lipo-
some contents leakage obtained in [22].
Fig. 2. Fluorescence anisotropy studies of the three peptides in DMPC/DMPS (3:2,
mol/mol) LUVs labeled with the ﬂuorescent probe DPH. The peptide/lipid molar
ratio was 1:20 in buffered saline solution (Tris–HCl, pH: 7.4). Peptide and lipid concentra-
tion into the cuvette were 5 μM and 75 μM, respectively. In the case of GBV-C/FP-HIV,
the peptide/peptide molar ratio was chosen according to the inhibition of liposome con-
tents leakage obtained in [22].
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(3:2, mol/mol) with anionic charge chosen to mimic cells infected
with HIV [24]. Exclusion pressure that indicates themaximumpenetra-
tion ability by the peptides into lipidmonolayers was 45.6mNm−1 and
40.7 mNm−1 for P58 and P59, respectively. These results were expect-
ed taking into consideration the data obtained in the previous section
and the charge inﬂuence in peptide/lipid interaction as described for
other similar peptides [19]. On another hand, the low insertion of P45
into phospholipid monolayers is likely due to the electrostatic repul-
sions since both peptide and lipid polar head are negatively charged.
3.3. Compression isotherms
π–A isothermsweremeasured to obtain basic information of the dif-
ferent peptides on the phase behavior under compression process. The
amount of peptide extended on the air/buffered surface was in all the
cases 1.6 × 1016 molecules. P45, P58 and P59 were able to form stable
monolayerswith a hysteresis cycle reproducible upon compression. Iso-
therms were characteristic of peptides with low molecular weight and
show well differentiated regions from which we can obtain several
characteristic parameters (Table 2). The lift-off area, deﬁned as the
mean molecular area when surface pressure has reached 1 mN m−1
[33] indicates that the peptides adopt an extended horizontal conﬁgura-
tion in the monolayer [34]. Extrapolated area or limiting area indicates
the area occupied by the molecule in the monolayer calculated in the
more condensed phase. In our experiments, these values increased
also in the same order being closer to the theoretical value of 1.75 nm2molec−1 found for aα-helix peptide oriented perpendicular to the inter-
face [35].3.4. Fluorescence anisotropy of membrane lipids
A step forward consisted in the analysis of the degree of peptide pen-
etration into bilayers assessed by ﬂuorescence anisotropy using two
ﬂuorescent probes that locate in different positions of the bilayer, DPH
(hydrophobic) and TMA-DPH (partially hydrophilic). No interactions
were observed in DMPC vesicles (zwitterionic) (data not shown)
while different behavior was seen with liposomes composed of
DMPC/DMPS (3:2, mol/mol) that hold negative charge. The peptides
changed the properties of the hydrophilic part of the bilayer as stated
by the results obtained with TMA-DPH (Fig. 1). As a general trend, in-
corporation of the peptides in the incubation media resulted in an in-
crease in the anisotropy (r) all over the temperature range (15 to
40°C). This is a proof of an increase in bilayer rigidity as a consequence
of the peptides. This change is more relevant for P45 and its
mixture with FP-HIV, being the highest r values those obtained with
P45/FP-HIV (2/1, mol/mol). P58, P59 and their mixtures with FP-HIV
present similar values at a temperature below the Tm when the mem-
brane is in a gel state. Above Tm the lines tend to superimpose that of
the control but differences are still evident. In the case of DPH, anisotropy
data is similar to the control at T below Tm of the lipid mixture. However,
we can distinguish different effects above Tm depending on the peptide
Fig. 3. AFM images of DMPC/DMPS (3:2, mol/mol) SLB before (A, B and C) and after incubation of: D) 5 μM FP-HIV, E) 10 μM P45 and F) 5 μM FP-HIV + 10 μM P45 for 30 min at room
temperature. Z scale bar is 20 nm.
Table 3
Height, roughness (Ra) and coveringpercentage values of the SLBs before and after 30 min
of peptide incubation.
SLB
FP-HIV P45 FP-HIV + p45
0 min h (nm) 5.3 ± 0.3 5.4 ± 0.4 5.5 ± 0.3
Ra (nm) 0.018 0.3 0.5
Covering (%) 55 78 63
30 min h (nm) 4.1 ± 0.4 1.9 ± 0.4 4.9 ± 0.5
Ra (nm) – 0.3 0.6
Covering (%) 30 86 60
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the lipid bilayer. This rigidifying effect is reduced by the presence of the
peptides. Particularly interesting is the effect observed for P45 that almost
abolishes FP-HIV penetration up to 35°C and, for that reason, this se-
quence was chosen for AFM studies.
3.5. Atomic force microscopy
AFM permits to visualize in real time the interaction of macro-
molecules with the surface of SLBs [30,36]. We have thus studied
the interaction of the different peptides with SLBs of DMPC/DMPS
(3:2, mol/mol) (Fig. 3). Fig. 3A, B and C represent the SLBs before
the injection of the corresponding peptides. Height, roughness (Ra)
and covering values can be found in Table 3. Fig. 3D shows the effect
of the injection of FP-HIV on the SLB to a ﬁnal concentration of 5 μM
after 30 min of incubation. From the image it is clearly seen the de-
stabilization of the SLB which results in a reduction of the thickness
of the SLB from 5.3 to 4.1 nm. But more importantly, the addition of
the FP-HIV promotes desorption of lipids composing the SLB as in-
ferred from the decrease in the covering of the mica surface, from
55% to 30%. Fig. 3E shows the effect of the injection of P45 to a ﬁnal
concentration of 10 μM on the SLB after 30 min of incubation. In
this case the SLB height is dramatically decreased, from 5.4 to
1.9 nm, together with an increasing of the surface covered by the
SPB. In Fig. 3F it is shown the SLB after the injection of a mixture of
FP-HIV and P45 in a molar ratio of 1:2 (5 μM FP-HIV and 10 μM of
P45). In this case, after 30 min of incubation the SLB is mostly intact,
both in height and in covering (see Table 3) suggesting a possible inter-
action of both peptides in solution before the interaction with the SLB.
To gain insight to this possible aggregation process we analyzed the
molecular structure of the FP-HIV and P45 through its amino acid se-
quence [37]. The de novo approach permits to predict the structure of
the FP-HIV and P45 peptides minimizing the energy. In Fig. 4A it isplotted the predicted structure at the minimum value of energy of FP-
HIV fromwhere it can be seen that FP-HIV presents a big hydrophobic re-
gion (pink ribbon). Therefore, FP-HIVmay interact with the DMPC/DMPS
(3:2, mol/mol) SLB through its hydrophobic region eroding the SLB sur-
face to formpeptide–lipidmixedmicelles. In Fig. 4B it is depicted the pre-
dicted structure at the minimum value of energy of P45 peptide. From
this image it is clearly seen that P45 is formed mainly by two β-sheet
structures (yellow ﬂat arrows). In this case the interaction of P45 with
the SLB composed of DMPC:DMPS is not so clear as before: i) P45 can
be adsorbed by its β-sheet structures ﬂat to the SPB surface; ii) P45 can
be absorbed inside of the SPB exposing the charged amino acids towards
the liquidmedia. Regardless of how thepeptide interactswith the SLB it is
not able to form holes that could disintegrate the SLB, under our experi-
mental conditions. Moreover, it seems to facilitate the spreading of the
SLB decreasing the line tension existing between the lipids forming the
SLB. In Fig. 4C it is depicted a possible interaction between FP-HIV and
P45, taking into account that: I) the hydrophobic regions of both peptides
could protect each other from their exposure to the water environment,
fact that could explain why the peptides incubated together nearly do
not interact with the SLBs, and ii) the molar ratio of 1 molecule of FP-
Fig. 4. Predictedmolecular structures at theminimum value of energy for FP-HIV A), P45 B) and a possible molecular organization, in solution, of the FP-HIV-P45mixture C). Color mean-
ings, pink: α-helix; yellow: β-sheet; red: anionic amino acid; green: cationic amino acid; blue: β-turn and white: unspeciﬁc.
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actions on the SLB.
4. Conclusions
The surface studies indicate that the three sequences have different
activity and ability to penetrate into lipid monolayers (Tables 1 and 2)
as a consequence of their amino acid distribution. Even though the pep-
tide charge isn't a determinant data to deﬁne their surface activity, it is
of great relevance in their penetration into DMPC/DMPS (3:2, mol/mol)
monolayers. P45 lacks of interaction with lipid monolayers of this com-
position because both, peptide and lipids, are negatively charged and re-
pulsion forces are dominant. The contrary is observedwith P58 and P59
that are positively charged and can insert into the monolayer up to ex-
clusion pressures higher than 32 mN m−1 that is the minimum
value that predicts the penetration into the biological membranes.
On another hand, when considering the effect of these peptides in
lipid bilayers, the results from ﬂuorescence anisotropy show that the
three peptides can modify the membrane behavior of the outer part of
the bilayer increasing its rigidity. However, the behavior is similar for
all the peptides and no changes in FP-HIV are observed in presence of
any of the GBV-C sequences. On another hand, studies of the interaction
of the peptides with the inner core of the membrane labeled with DPH
showed that the three peptides were able to decrease the rigidifying ef-
fect of FP-HIV in the bilayer. This wasmore relevant for P45 than for P58
or P59. For that reason, P45 has chosen for further experiments to eluci-
date the changes involved in bilayer morphology in presence and ab-
sence of FP-HIV.
From AFM images can be inferred different modes of action of FP-HIV
and P45. On one hand, FP-HIV interacts with the SLB eroding and solubi-
lizing the surfaces of the lipid bilayer while the edges of the SLBwere un-
altered. Due to lipid was not deposited on the exposed mica it is
reasonable to suppose that solubilized lipids were set aside from the
scanned region. On the other hand, P45 does not destroy the SLB. From
the image it seems that P45 absorbs into the SLB decreasing the lateral
surface pressure inside of the SLB, fact that promotes the spreading of
the lipids in the SLB on the exposed mica surface. As expected by results
previously discussed in this paper, when FP-HIV and P45 are incubated
together at a molar ratio of 1:2 neither the solubilization nor the spread-
ing effects of the SLB were observed. When both peptides are mixed be-
fore the injection on the SLB, they seem to form aggregates blocking to
each other their active regions against the SLB. Therefore, it is reasonable
to conceive an aggregate in solution where the β-sheets from P45 couldcover the α-helix structure of FP-HIV. Therefore this new conformation
could prevent the anchorage of FP-HIV to the SLB surface impeding the
formation of holes that would destroy the SLB.
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